Nuveen LLC Takes Position in Atossa Genetics Inc. $ATOS

Nuveen LLC acquired a new stake in Atossa Genetics Inc. (NASDAQ:ATOS) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 170,733 shares of the company’s stock, valued at approximately $115,000. Nuveen LLC owned 0.13% of Atossa Genetics as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ATOS. Wells Fargo & Company MN lifted its position in shares of Atossa Genetics by 30.7% during the 4th quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock valued at $68,000 after acquiring an additional 16,853 shares during the last quarter. Barclays PLC lifted its position in shares of Atossa Genetics by 14.5% during the 4th quarter. Barclays PLC now owns 191,954 shares of the company’s stock valued at $181,000 after acquiring an additional 24,236 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Atossa Genetics by 7.5% during the fourth quarter. Northern Trust Corp now owns 1,025,724 shares of the company’s stock valued at $968,000 after purchasing an additional 71,525 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Atossa Genetics by 51.3% during the fourth quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock valued at $105,000 after purchasing an additional 37,809 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Atossa Genetics during the fourth quarter valued at $28,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ATOS. Ascendiant Capital Markets upped their target price on Atossa Genetics from $7.25 to $7.50 and gave the company a “buy” rating in a report on Friday, June 6th. Craig Hallum raised Atossa Genetics to a “strong-buy” rating and set a $4.00 target price for the company in a report on Thursday, June 5th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to MarketBeat.com, Atossa Genetics has a consensus rating of “Buy” and a consensus price target of $6.17.

Atossa Genetics Trading Up 2.2%

Shares of Atossa Genetics stock opened at $0.79 on Monday. The stock has a 50-day moving average price of $0.82 and a 200 day moving average price of $0.79. The company has a market cap of $101.79 million, a P/E ratio of -3.43 and a beta of 1.10. Atossa Genetics Inc. has a 1 year low of $0.55 and a 1 year high of $1.66.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). On average, equities analysts forecast that Atossa Genetics Inc. will post -0.22 earnings per share for the current fiscal year.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.